logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Zoptarelin doxorubicin for locally advanced, recurrent or metastatic endometrial cancer — second line

< Back

Zoptarelin doxorubicin for locally advanced, recurrent or metastatic endometrial cancer — second line

Drugs

Cancer and Palliative Care

July 2016


Zoptarelin doxorubicin is a new chemotherapy drug for the treatment of advanced endometrial cancer delivered straight into the bloodstream. Some studies have suggested zoptarelin doxorubicin may be helpful for women whose first treatment has failed and whose disease has spread and more studies are now aiming to show how well it works and that it is safe to use.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

PDF Report



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts